title: GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
abstract: OBJECTIVE
  To evaluate, whether Gonadotropin-releasing hormone-agonist (GnRH-agonist or GnRH-ag) trigger in patients undergoing the ultrashort GnRH-ag/GnRH-antagonist (GnRH-ant) protocol is as effective as in patients at high risk to develop severe ovarian hyperstimulation syndrome (OHSS), who undergo the multidose GnRH-ant protocol.
  
  
  METHODS
  Cohort study.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  All consecutive women aged ≤35 years admitted to our IVF unit from January 2011 to October 2011 who reached the ovum pick-up stage.
  
  
  METHODS
  Triggering final oocytes maturation by GnRH-ag instead of hCG, in high-responder patients undergoing either the ultrashort GnRH-ag/GnRH-ant or the multidose GnRH-antagonist controlled ovarian hyperstimulation (COH) protocols.
  
  
  METHODS
  Ovarian stimulation characteristics, percentage of mature oocytes, fertilization and pregnancy rates.
  
  
  RESULTS
  No inbetween groups differences were observed in ovarian-stimulation related variable, percentage of mature oocytes, fertilization or pregnancy rates. No case of moderate-severe OHSS was reported in the study, or the control groups.
  
  
  CONCLUSIONS
  Three consecutive doses of daily GnRH-ag administration at the beginning of ultrashort flare GnRH-ag/GnRH-ant COH protocol, did not interfere with the ability of the GnRH-ag to trigger final oocytes maturation at the end of the COH cycle.
authors.affiliation: Department of Obstetrics and Gynecology, Barzilai Medical Centre, Ashkelon, Israel. raoulo@barzi.health.gov.il
authors.forename: Raoul
authors.initials: R
authors.lastname: Orvieto
authors.forename: Ravit
authors.initials: R
authors.lastname: Nahum
authors.forename: Efraim
authors.initials: E
authors.lastname: Zohav
authors.forename: Gad
authors.initials: G
authors.lastname: Liberty
authors.forename: Eyal Y
authors.initials: EY
authors.lastname: Anteby
authors.forename: Simion
authors.initials: S
authors.lastname: Meltcer
mesh_terms: D000328:Adult; D015331:Cohort Studies; D016208:Databases, Factual; D005260:Female; D005306:Fertilization / Q000187:drug effects; D005307:Fertilization in Vitro / Q000379:methods*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000037:antagonists & inhibitors*; D006062:Gonadotropins / Q000008:administration & dosage; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy* / Q000453:epidemiology; D008186:Luteolytic Agents / Q000008:administration & dosage; D009865:Oocytes / Q000166:cytology / Q000187:drug effects; D016471:Ovarian Hyperstimulation Syndrome / Q000453:epidemiology / Q000517:prevention & control; D010060:Ovulation / Q000187:drug effects* / Q000502:physiology; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D012307:Risk Factors; D017329:Triptorelin Pamoate / Q000008:administration & dosage
chemical_list: D006062:Gonadotropins; D008186:Luteolytic Agents; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone